Bio-data

R. Mahesh*; M. Pharm., Ph.D*.
Professor,
Department of Pharmacy
Birla Institute of Technology & Science, Pilani
Pilani Campus, Rajasthan-333031, India.
Email: rmahesh@pilani.bits- pilani.ac.in;

Tel: +91-1596-515-207/226**;** **Mobile:** +91-9414082670

Name	: R. Mahesh
Sex	: Male
Date of Birth	: 7th May, 1965
Qualification	: M.Pharm., Ph.D
Designation	: Professor
Address:	
Office	: Professor, Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Pilani Campus, Vidya Vihar, Rajasthan - 333031, India
Residence	: House No. 147, Shiv Ganga Marg, Birla Institute of Technology & Science, Pilani, Pilani Campus, Vidya Vihar, Rajasthan- 333031, India
Year of award of Doctoral degree	: October, 1997
Subject Expert & Research Areas	: **Medical Chemistry and Pharmacology**: *Neuropsychopharmacology*-Depression, Anxiety, Alzheimer's & Parkinson's Diseases, Depression Co-morbid with Metabolic Disorders *Malaria*

Detailed Bio-Data

Teaching and Research Experience

a. Teaching:

Duration	Institution	Courses taught and introduced*
1989 to date	BITS, Pilani	First Degree (Under-graduate) Medicinal Chemistry Chemistry of Synthetic Drugs* Applied Pharmaceutical Chemistry* Instrumental Methods of Analysis Bioethics & Biosafety* Application of Biomedical Instrumentation Techniques in Healthcare* Higher Degree (Post-Graduate) Advanced Medicinal Chemistry* Computer Aided Drug Design* Advanced Pharmacology* Molecular Biology and Immunology* Screening Methods & Techniques in Pharmacology* Fermentation & Biotechnology* Disinfection and Sterilization Clinical Pharmacy and Therapeutics*

b. Research:

Duration	Institution	Particulars of work done/Area
1989 to date	BITS, Pilani	Medicinal Chemistry and Neuro Psycho-pharmacology: Design, synthesis and Neuro-Psycho-pharmacological investigations pertaining to serotonergic modulators with special emphasis on depression and co-morbid disorders such as hypertension, diabetes, anxiety and obesity.

Academic Designations Held (1989 till date):

2010 - till date	Professor
2005 – 2010	Associate Professor
2000 – 2005	Assistant Professor
1989 – 2000	Lecturer
Post Ph.D. Experience (since Oct 1997)	~ 22.5 years
Teaching, Research Experience (since July,1989)	~ 30 years

Administrative Experience:

1	Dean, Faculty Affairs Division	May 2011 – May 2018
2	Chief, Community Welfare and Societal Development Unit	August 2010 – September 2012
3	Head – Department of Pharmacy	August 2002 - July 2010
4	Co-ordinator/In-Charge, Central Analytical Laboratory (CAL)	Nov 1998 - July 2010
5	In-Charge, Central Animal Facility	~March 2005 – July 2010
6	Resident Warden- Boys Hostel	July 1995- July 2005
7	Student Welfare Division - Nucleus member of the Division	July 1996 – April 2008
8	Academic Registration and Counselling Division	July 1989 - July 1996

Responsibilities and activities related to some of the aforementioned administrative functions are given below.

Dean, Faculty Affairs Division (FAD)

- Responsibilities as Dean of Faculty Affairs included creation of office of Faculty Affairs as well as introducing and streamlining various processes and procedures, as given below.

- Faculty Appointments: tenured -on-campus, off campus; non-tenured-on-campus, off-campus. Creation of complete Recruitment Process cycle protocol in association with a RPO – for both on-campus and off-campus tenure track faculty recruitment for the 3 campuses in India.

- Appointment of Non-tenured (short-term) faculty – processes and related guidelines
- Revision of pay structure and removal of disparities in pay.
- Guidelines and procedures related to exposure of faculty to universities abroad
- Guidelines and procedures related to immersion of faculty in industries in India to enhance faculty- industry engagement
- Guidelines related to the appointment of Guest Faculty, DST-INSPIRE fellows at BITS campuses
- Revision of policies related to Medical reimbursements, Institutional support for staff and staff spouse Children Education.
- Creation of faculty induction kit for new joiners
- Implementation of Annual performance Appraisals for faculty and related procedures.
- Guidelines for creating Chair Professorships, OPERA awards to attract and retain senior and new faculty, respectively.
- Faculty extensions, promotions, regularization, renewal of appointments and related
- issues, identification of potential faculty at senior levels through consultants.
- Dubai campus: - streamlining and implementation of faculty appraisals, addressing faculty issues with creation of new pay structure, employment terms and conditions, benefits, promotions, faculty recruitment process
- Off-Campus programmes: Streamlining the recruitment process, re-designations of existing faculty in line with new positions, creation of practice track for faculty not involved in research, streamlining the process of faculty industry immersion process
- Creation of Faculty Affairs Division Website with all information associated with the above and population of information including off-campus and non-teaching staff- appointments, policies, guidelines, opportunities, appraisals, others. (http://www.bits-pilani.ac.in/university/fad/Policies)

Chief, Community Welfare and Societal Development Unit (CWSDU)

a) Streamlined house allotment policy and guidelines and made allotments transparent.

b) Involved in renovation of several quarters

c) Infant Care Centre (currently rechristened as Blossoms Kids Zone) was renovated and upgraded

d) Medical Centre and Medical Shop were renovated and redesigned respectively, with addition of 3 new rooms in Medical Centre with facility of monitoring, observation rooms

with beds and related infrastructure, facilitated visit of specialists, enhanced testing procedures with new equipments.

e) Involved in introducing "best performer Awards" for non-teaching staff, related procedures.

f) Facilitated procurement of new Critical Care Ambulance, body freezer and new digital X-ray machine for local hospital.

g) Introduced a car pool scheme for students and staff and circular bus transport within campus during new admission reception of reporting students.

h) Conducted "Passport Mela" for students, staff and their family members as well as their issue, coordinating with Regional Passport Office twice.

i) Health Camps, Pollution check for all vehicles in campus were conducted.

j) Medical Centre registration and Medical Shop billing procedures were upgraded.

k) Involved in facilitating issue of Aadhar Card by organizing camp within campus.

l) Facilitated creation of 2 new parks for children near teaching and non-teaching staff quarters with play equipments.

m) Facilitated remodeling of BITS-CO-OP stores Vegetable shop, with provision car parking facility.

n) Participated and provided inputs for project "Parivarthan" as Member, User Council.

Head, Department of Pharmacy (activities involved in brief other than routine):

a) Served as Head of the Department for eight years

b) Member of several committees such as Senate, Recruitment, Research Board, BITS Co-operative stores, Selection, Institutional Animal, Human Ethics, Library, Admissions, etc.

c) Member, organizing committee for several national and international seminars and conferences.

d) Renovated most of the B.Pharm. and M.Pharm. Laboratories with UGC-DRS SAP-Level- I and Level – II (five years each) fund support through proposals.

e) Obtained DST-FIST support for up-gradation of laboratory facilities with new equipments.

g) Curricular Development:

- Involved in introducing a new programme **Master's in Public Health** jointly offered with Bio-Sciences Group and courses for the degree (was deputy-coordinator and later co-ordinator for the programme) with funded support from proposal sanctioned by UGC under "Innovative New Programmes" scheme.
- Involved in developing several courses at the first degree as well as higher degree level including programme structure for M.Pharm. With specializations in Pharmaceutics and Medicinal Chemistry.

- Standardized animal models for the evaluation of co-morbid depression treatment resistant depression namely:

  a) olfactory bulbectomy in rats and

  b) traumatic brain injury models that mimic human depression state.

Co-ordinator, Central Analytical Laboratory (CAL)

a) Added new equipments such as HPTLC, HPLC's, moisture balance, analytical balances, Brookfield viscometer, stability chambers, visual melting range apparatus, etc. with funding from various sources.

b) Developed Standard Operating Procedures for all analytical equipments in CAL.

b) Updated the Laboratory Experiment Instruction Manual for all experiments for the course Instrumental Methods of Analysis

In-Charge, Central Animal Facility

Conceptualized, designed, created the new Central Animal Facility with Institutional support including infrastructure development for teaching and research in all relevant disciplines of the Institute. *(Currently houses several small animals for research with CPCSEA approval for housing as well as breeding licenses).*

Student Welfare Division (SWD)

a) Nucleus member of Student Welfare Division for 15 years- involved in several developmental activities such as automation of student dues, issue of certificates, standardization of procedure for first degree reception, health club and student's activity centre (SAC) development, etc.

b) In-charge- processing and member of scholarships committee of Institute's merit-cum-means scholarships for several years – involved in streamlining and automation of the process.

c) In-Charge of Recreational Activities Forum – Streamlined all R.A.F. activities and procedures, developed assets.

d) Involved in the design and development of squash and badminton courts at Student Activities Centre.

Academic Registration and Counselling Division (ARCD)

a) In-Charge, substitution and withdrawal from courses since joining as nucleus member of Academic Registration and Counselling Division and later-

b) In-Charge, Registration, which includes Registration of students in programmes of all programmes of the Institute.

Projects Details as Principal Investigator/Co-Investigator (ongoing / started/ completed in the last 5 years)

1. Synthesis and pharmacological evaluation of novel phosphodiesterase 4 inhibitors for their anti-depressant and anxiolytic potential (**DBT, Rs. 51.69 Lakhs; three years, Completed March 2013**)

2. Novel Neuro-Pharmacological Agents for the Treatment of Depression, Anxiety, Cognitive Dysfunction and CCIE: Design, Synthesis and Screening of Potential Serotonergic Modulators **(ICMR, Rs. 31.20 Lakhs; 3 years, Completed Dec 2013)**

3. International malarial research consortium for the development of novel classes of antimalarials, Indo-Canadian DBT Project (Indo-Canadian Joint Research Consortium on Anti-Malarials; **DBT ; Rs, 35.50 Lakhs; three years, Phase-I; Completed Sept 2013**)

4. International malarial research consortium for the development of novel classes of antimalarials, Indo-Canadian DBT Project (Indo-Canadian Joint Research Consortium on Anti-Malarials; **DBT ; Rs, 21.86 Lakhs; two years, Phase-II; Completed FY 2016-17**)

5. Infrastructural development of the department (level II) (**UGC Rs. 72 Lakhs; five years**) - Deputy Co-ordinator.

6. Design and Synthesis of Novel Agents for the Management of Rheumatoid Arthritis, (UGC**, 2010-13, 11.98 Lakhs, three years, Completed August 2013**), Co-Investigator.

Besides the above, few minor research projects have been completed in the past.

As head of the Department, was instrumental in submitted proposals for upgrading Departmental infrastructure for research and academics through UGC –DRS-SAP Level I and II, DST –FIST Level I and II. Funds received have been utilized for enhancing research equipments assets. Pharmacy laboratories were upgraded with additional funds of Rs. 40.00 lakhs obtained from UGC for infrastructural development over 2 years.

Patents

1. Radhakrishnan Mahesh, Muthu Venkatesh Sudali '*PDE4 inhibitor compounds for treating anti-depressant and anxiolytic related disorders',* - Application No. 1290/DEL/2014 dated 15/05/2014 (Patent Pending)- FER filed Jan., 2020

2. Sushil Kumar Yadav, Mahesh Radhakrishnan, Vishal Saxena – 'Non-enzymatic method for large scale isolation of β-casein from milk', - Application No. 201811018301, dated 16th May, 2018 (Patent Pending).

3. Sushil Kumar Yadav, Mahesh Radhakrishnan, Vishal Saxena- : 'A Method for determining A1/A2 genotype of milch animals',- Application No: 201911018953, dated 13th May, 2019 (Patent Pending)

Awards and Honors:

- DBT, ICMR and APTI Sponsored National Conference : Best Poster (1st Prize), 2016
- NIPICON International Conference : Best Poster (IInd Prize), 2014
- Pharmanext (AIPER) : Best Poster, 2012
- Indian Pharmaceutical Association : Best Poster (IInd Prize), 2012
- Indian Pharmacological Society International Convention : Best Poster (Neuro Pharmacology), 2011
- Indian Pharmacological Society International Convention : PC Dandiya Award, 2011
- Assoc. of Pharm. Teachers of India Conference : Best Poster, 2009
- Indian Pharmacological Society International Convention : Best Poster, 2008
- Indian Pharmaceutical Congress Annual Convention : Best Paper, 2005

- **Best Published Paper Award (Assoc. of Pharm. Teachers of India Conf. 2014)**
  Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award
  (Best published paper in Ind. J. Pharm. Edu. and Res. - Pharmacology)

- **Best Published Paper Award (Indian Pharmacology Society Conf. 2013)**
  NN Dutta Prize (Best Published Paper in Indian Journal of Pharmacology)

- **Best Published Paper Award (Assoc. of Pharm. Teachers of India Conf. 2012)**
  Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award
  (Best published paper in Ind. J. Pharm. Edu. and Res. - Pharmacology)

- **Best Published Paper Award (Assoc. of Pharm. Teachers of India Conf. 2011)**
  Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award
  (Best published paper during the year in Ind. J. Pharm. Edu. and Res. - Pharmacology)

Thesis Guided:

Ph. D: **Completed: 12**
(5 in Medicinal Chemistry;
6 in Pharmacology
1 in Veterinary Pharmacology)

- Doctoral Advisory Committee member for several Ph.D. candidates

Details of Ph.D. thesis guided till date:

S.No.	Name of Candidate	Thesis Title	Area	Start of Ph.D.-Year of Award	Status
1	Venkatesha Perumal R	Design Synthesis and pharmacological evaluation of novel serotonergic 5HT3 receptor antagonist as potential agents for the treatment of cancer chemotherapy induced emesis	Drug design and Development, Synthetic Medicinal Chemistry	August, 2001 - September, 2005	Completed
2	RajKumar R	Behavioural Neuropharmacological Studies of Selected Serotonin Type-3 Receptor Antagonists as Potential Anti-depressants	Neuropsycho-pharmacology division, (Drug discovery, standardization and development of new animal model)	August, 2004 - March 2008	Completed
3	Dilip Kumar Pandey	Neurobehavioural and Neurochemical Evaluation of Selected Monoaminergic Modulators in Animal Models of Comorbid Depression and Anxiety	Neuropsycho-pharmacology division, (Drug discovery, standardization and development of new animal model)	August, 2007 - March 2011	Completed
4	T. Devadoss	Novel Quinoxaline Carboxamides: Design, Synthesis And Neuro-Pharmacological Evaluation as Anti-depressants, Anxiolytic And in the Management of Cancer Chemotherapy-Induced Nausea and Vomiting	Drug design and Development, Synthetic Medicinal Chemistry	December, 2007 - January 2012	Completed
5	Shvetank Bhatt	Behavioural and Neuropharmacological Screening of Potential Serotonergic Ligands for Co-morbid Depression, Anxiety and Related Disorders such as Cancer Chemotherapy Induced Nausea and Vomiting (CINV)	Neuropsycho-pharmacology division, (Drug discovery, standardization and development of new animal model)	October, 2008 - March, 2015	Completed

6	Arghya K Dhar	Novel Neuro-Pharmacological Agents for the Treatment of Depression, Anxiety, Cognitive dysfunction and Cancer Chemo- Therapy Induced Emesis: Design synthesis and Screening of Potential Serotonergic Modulators	Drug design and Development, Synthetic Medicinal Chemistry	January, 2010 - May, 2016	Completed
7	Ankur Jindal	Behavioral and Neuropharmacological Screening of Phosphodiesterase4 (PDE4) Inhibitors for Anti-depressant and Anxiolytic Potential	Neuropsycho-pharmacology division, (Drug discovery, standardization and development of new animal model)	January, 2010 - December, 2015	Completed
8	Muthu V. Sudali	Design, Synthesis and Pharmacological Evaluation of Novel Phosphodiesterase-IV inhibitors for their Anti-depressant and Anxiolytic Potential	Drug design and Development, Synthetic Medicinal Chemistry	June, 2010 - Octiber, 2015	Completed
9	Sourabh Mundra	Design, Synthesis and screening of Potential Anti-malarial Agents.	Drug design and Development, Synthetic Medicinal Chemistry	September, 2010 - June, 2017	Completed
10	Deepali Gupta	Behavioral and Neuro-pharmacological Screening of Potential Serotonergic Ligands for Co-morbid Depression	Neuropsycho-pharmacology, (Drug discovery, standardization and development of new animal model)	August, 2011 - April, 2017	Completed
11	Yeshwant Kurhe	Behavioral and Neuropharmacological Screening of Potential Serotonergic Modulators for Depression Comorbid with Obesity	Neuropsycho-pharmacology, (Drug discovery, standardization and development of new animal model)	January, 2012 - January, 2018	Completed
12	Sushil Yadav	Isolation and Characterization of Genetic Variants of Beta Casein From Cow Milk and to Study Their Effects on Osteoporosis	Neuropsycho-pharmacology, Veterinary Pharmacology and Biotechnology	August, 2012 – Oct., 2019	Completed

Higher Degree: Guided several M. Pharm. students for various projects in the area of New Drug Design and Synthesis, Neuro-psychopharmacology, Design and development of new animal models, with special reference to serotonergic modulators and related disorders. Many have culminated in conference presentations and or publications.

First Degree: Guided two (completed) first degree thesis students and currently guiding one first degree student in the area of Neuro-psychopharmacology, Design and Development of new Animal Models and related protocol standardization. Guided several B.Pharm. Students on Special Projects, Lab. Oriented Projects, Study Oriented Projects, Computer Projects. A few have culminated in conference presentations and or publications.

Conferences Organized:

Organizing Committee Member/Co-ordinator:

a) International Symposium on Recent Advances in Drug Design and Drug Delivery Systems, February 2005.

b) International Workshop on Drug Design, February 2005.

c) International Symposium on Public Health awareness (in association with Bio-Sciences Group), March,2005

d) National Symposium on Challenges in Drug Discovery Research: Networking Opportunities between Academia and Industry, (in association with Chemistry Group) April, 2006

e) International Symposium on "Emerging Trends in Life Sciences Research" (in association with Bio-Sciences Group), March,2009

Professional Activities:

(A) Memberships of Professional Bodies:

1. Member, Board of Studies, (Pharmacy), DIT University, Dehradun
2. Member- Selection Committee for JRF/SRF- CSIR
3. Life Member - Society of Neurochemistry, India
4. Life Member - Indian Pharmacological Society
5. Life Member - Association of Pharmacy teachers of India

(B) Referee for Journals:

1. Chemical Biology and Drug Design – Publisher - Willey
2. Indian Journal of Medical Research- Publisher - ICMR
3. Indian Journal of Experimental Biology- Publisher - NISCAIR
4. Indian Journal Of pharmaceutical Sciences- Publisher- Medknow

(C) Member, Committees:

- Member, Research and Recognition Committee, SPP School of Pharmacy & Technology Management, Narsee Monjee Institute of Management Sciences, Mumbai

Book Chapter:

- Yong –Ku Kim (editor) et al., 'Understanding Depression …"- Springer Nature Singapore pvt ltd., Vol-2, Chapter-17, pp-235-249, 2018 with research scholar, Ms. Deepali Gupta.

Research Publications *(International and National)*

International

1. Kurhe Y, **Mahesh R**, Devadoss T. Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice. Psychopharmacology 2017; 234, 1165-1179. ***(Springer) (IF-3.87)***

2. Mundra S, Thakur V, Bello A. M, Rathore S, Asad M, Wei L, Yang J, Chakka S. K, Mahesh R, Malhotra P, Mohmmed A, Kotra L. P. A novel class of Plasmodial ClpP protease inhibitors as potential antimalarial agents. Bioorganic & Medicinal Chemistry 2017; 25, 5662-5677 (IF-2.793)

3. Bhatt S, **Mahesh R**, Devadoss T, Jindal A. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice. Journal of Basic and Clinical Physiology and Pharmacology 2016, Volume 28, Issue 2, Pages 101– 106, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, ***(De Gruyter)***

4. Bhatt S, **Mahesh R**, Jindal A, Devadoss T. Neuropharmacological and neurochemical evaluation of Nn-propyl-3- ethoxyquinoxaline-2- carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant-and anxiolytic-like potential using traumatic brain injury model in rats. Journal of Basic and Clinical Physiology and Pharmacology 2016 Volume 28, Issue 2, Pages 93–100, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, ***(De Gruyter)***

5. Kurhe Y, **Mahesh R.** Pioglitazone, a PPAR-Ɣ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. Neurobiology of Stress 2016; 3, 114-121. ***(Elsevier) (IF-1.0)***

6. Bhatt S, Bagal SM, Butola S, Dhar AK, **Mahesh R**. Antidepressant-and anxiolytic-like effect of novel 5-hydroxytryptamine3 receptor antagonist 2-[4-(3-chlorophenyl) piperazin-1-yl]-1, 8-naphthyridine-3-carboxylic acid (7e)-: An approach using rodent behavioral antidepressant and anxiolytic test battery. International Journal of Nutrition, Pharmacology, Neurological Diseases 2016; 6, 81-89. ***(Medknow) (IF-0.6)***

7. Gupta D, Prabhakar V, **Radhakrishnan M**. 5HT3 receptors: Target for new antidepressant drugs. Neuroscience & Biobehavioral Reviews 2016; 64, 311-325. ***(Elsevier) (IF-10.52)***

8. Gupta D, Thangaraj D, **Radhakrishnan M**. A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced

depressive phenotypes in mice: Modulation of serotonergic system. Behavioral Brain Research 2016; 297, 41-50. ***(Elsevier) (IF-3.0)***

9. Kurhe Y, **Mahesh R**. Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission. Pharmacology Biochemistry and Behavior 2015; 136, 107-116. ***(Elsevier) (IF-2.78)***

10. Mundra S, **Mahesh R**. Pyridine-based microwave assisted one-pot synthetic protocol for the synthesis of ethyl 3-substituted-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates. Research on Chemical Intermediates 2016; 42, 4207-4219 ***(Springer) (IF- 1.3)***

11. Kurhe Y, **Mahesh R**. Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonists as novel therapeutic intervention. Asian Journal of Psychiatry 2015; 17, 3-9. ***(Elsevier) (IF-0.6)***

12. Chakka S. K, Kalamuddin M, Mundra S, **Mahesh R**, Malhotra P, Mohmmed A, Kotra L. P. Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents. Bioorganic & Medicinal Chemistry 2015; 23, 2221-2240 ***(Elsevier) (IF-3.3)***

13. Gupta D, **Mahesh R**, Kurhe Y. Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice. Steroids 2015; 96, 95-102. ***(Elsevier) (IF-2.71)***

14. Jindal A, **Mahesh R**, Bhatt S. Etazolate, a Phosphodiesterase 4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy. Psychopharmacology, 2015; 232, 623-637. ***(Springer) (IF-3.396)***

15. Jindal A, **Mahesh R**, Bhatt S. Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic-pituitary-adrenal axis, cAMP signaling aspects and antioxidant defense system. Pharmacology Biochemistry and Behavior 2015; 132, 20-32. ***(Elsevier) (IF-2.78)***

16. Kurhe Y, **Mahesh R**, Devadoss T. QCM-4, a 5-HT3 receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice. Biochemical and Biophysical Research Communications 2015; 456, 74-79. ***(Elsevier) (IF-2.281)***

17. Mundra S, **Mahesh R**. Evaluation of novel 1-(4-(substituted)piperazin-1-yl)-2-(phenylamino)ethanone derivatives as Falcipain-2 inhibitors. Journal of young Pharmacist 2015; 7, 96-105. ***(Elsevier) (IF-0.5)***

18. Dhar AK, **Mahesh R**, Jindal A, Bhatt S. Piperazine analogues of naphthyridine-3-carboxamides and indole-2-carboxamides: Novel 5-HT3 receptor antagonists with antidepressant like activity, Archive Der Pharmazie 2015; 348, 34-45. ***(Wiley Online Library) (IF-1.39)***

19. Kurhe Y, **Mahesh R**, Gupta D, Thangaraj D. Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery. Journal of Basic and Clinical Physiology and Pharmacology, 2015; 26, 25-33. ***(De Gruter)(IF-0.6)***

20. **Mahesh R**, Mundra S, Devadoss T. Design, synthesis and evaluation of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N phenylacetamide derivatives as a new class of falcipain-2 inhibitors. Arabian Journal of Chemistry 2014; 20, 212-224. ***(Elsevier) (IF-2.7)***

21. Gupta D, **Mahesh R**, Kurhe Y. Ondansetron, a 5HT-3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system. European Journal of Pharmacology 2014; 744, 59-66. ***(Elsevier)*** *(**IF- 2.754**)*

22. Dhar AK, **Mahesh R**, Jindal A, Devadoss T, Bhatt S. Design, Synthesis, and Pharmacological Evaluation of Novel 2-(4-substituted piperazin-1-yl)1, 8 Naphthyridine 3-Carboxylic Acids as 5-HT3 Receptor Antagonists for the Management of Depression. Chemical Biology & Drug Design 2014; 84, 721-31. ***(Willey) (IF-2.50)***

23. Kurhe Y, **Mahesh R**, Gupta D, Devadoss T. QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: An approach based on behavioral and biochemical investigations. European Journal of Pharmacology 2014; 740, 611-618. ***(Elsevier) (IF-2.75)****.*

24. Kurhe Y, **Mahesh R,** Gupta, D. Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. Metabolic Brain Disease 2014; 29, 701-710. ***(Springer) (IF-2.39)***.

25. Gupta, Deepali; Radhakrishnan, Mahesh; Kurhe, Yeshwant; Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety, European journal of pharmacology, 742 - 94-101 2014, Elsevier

26. Gupta D, **Mahesh R**, Kurhe Y, Thangaraj D, Prabhakar V, Kanade P. Antidepressant-like effects of 6z, a novel 5HT3 receptor antagonist in acute and chronic mouse models of depression. Acta Pharmacologica Sinica 2014; Accepted. ***(Nature) (2.496)***.

27. Kurhe Y, **Mahesh R**, Gupta D. Effect of a Selective Cyclooxygenase Type 2 Inhibitor Celecoxib on Depression Associated with Obesity in Mice: An Approach Using Behavioral Tests. Neurochemical Research 2014; 39:1395-1402. ***(Springer) (IF-2.55)***

28. Bhatt S, **Mahesh R**, Jindal A, Devadoss T. Protective effects of a novel 5-HT3 receptor antagonist, *N*-n-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronicunpredictable mild stress–induced behavioral changes and biochemical alterations. Pharmacology Biochemistry Behavior 2014; 122: 234-239. ***(Elsevier) (IF-2.75)***

29. Bhatt S, **Mahesh R**, Jindal A, Devadoss T. Neuropharmacological Effect of Novel 5-HT3 Receptor Antagonist, *N*-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on Chronic Unpredictable Mild Stress-Induced Molecular and Cellular Response : Behavioural and Biochemical Evidences. P harmacological Reports 2014; 66: 804-810. ***(Elsevier) (IF-1.96)***

30. Gupta D, **Radhakrishnan M**, Thangaraj D, Kurhe Y. Antidepressant and anti-anxiety like effects of 4i (3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT receptor antagonist in acute and chronic neurobehavioral rodent models. European Journal of Pharmacology 2014; 735: 59-67. ***(Elsevier) (IF-2.592)***

31. Gupta D, **Radhakrishnan M**, Kurhe Y. Insulin reverses anxiety-like behavior evoked by streptozotocin-induced diabetes in mice. Metabolic Brain Disease, 2014; 29, 737-46. ***(Springer) (IF-2.33)***

32. Gupta D, Kurhe Y, **Radhakrishnan M**. Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system. Physiology & Behavior 2014; 129: 73-78. ***(Elsevier) (IF-3.1)***

33. **Mahesh R**, Dhar AK, Jindal A, Bhatt S. Design, synthesis and evaluation of anti depressant activity of novel 2-methoxy 1, 8 naphthyridine 3-carboxamides as 5-HT3 receptor antagonists. Chemical Biology & Drug Design 2014; 83, 583-91. ***(Wiley Online Library) (IF-2.50)***

34. Kurhe Y, **Mahesh R**, Gupta D, Thangaraj D. QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice. Journal of Pharmacy and Pharmacology 2014; 66, 122-32. ***(Wiley Online Library) (IF-2.03)***

35. Bhatt S, **Mahesh R**, Jindal A, Devadoss T. Neuro-pharmacological evaluation of structurally novel 5-hydroxytryptamine type 3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) for its anxiolytic potential. International Journal of Nutrition, Pharmacology, Neurological Diseases 2013; 3, 383-387. ***(Medknow)***

36. Jindal A, **Mahesh R**, Bhatt S. Etazolate rescues behavioral deficits in chronic unpredictable stress model: Modulation of hypothalamic-pituitary-adrenal axis activity and brain-derived neurotrophic factor level. Neurochemistry International 2013; 63, 465-75. ***(Elsevier) (IF- 2.659)***
37. **Mahesh R,** Dhar AK, Jindal A, Bhatt S. 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: Novel 5-HT3 receptor antagonists with anxiolytic like activity in rodent behavioral models. Canadian Journal of Physiology and Pharmacology 2013; 91, 848-54. ***(NRC Research Press) (IF-1.556)***

38. Gautam BK, Jindal A, Dhar AK, **Mahesh R**. Antidepressant - Like Activity of 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-3-carboxylic acid (7a), a 5 -HT(3) Receptor Antagonist in Behaviour Based Rodent Models: Evidence for the Involvement of Serotonergic System. Pharmacology Biochemistry and Behavior 2013; 109, 91–97. ***(Elsevier) (IF-2.608)***

39. Jindal A, **Mahesh R,** Bhatt S. Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage. Pharmacology Biochemistry and Behavior 2013; 105, 63-70. ***(Elsevier) (IF-2.608)***

40. Jindal A, **Mahesh R,** Gautam B. Anxiolytic-like effect of linezolid, an oxazolidinone class antibiotic in experimental mouse models of anxiety**.** Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013; 40, 47-53. ***(Elsevier) (IF-3.552)***

41. Jindal A, **Mahesh R,** Gautam B, Bhatt S, Pandey D. Antidepressant-like effect of etazolate, a cyclic nucleotide Phosphodiesterase 4 inhibitor – an approach using rodent behavioral antidepressant tests battery. European Journal of Pharmacology 2012; 689, 125-131. ***(Elsevier) (IF-2.592)***

42. **Mahesh R,** Devadoss T, Pandey DK, Dhar AK Sudali M, Mundra S, Bhatt S, Jindal A. Ligand-Based Design, Synthesis and Pharmacological Evaluation of 3-Methoxyquinoxalin-2-Carboxamides as Structurally Novel Serotonin Type-3 Receptor Antagonists. Archive Der Pharmazie 2012; 345, 687-94. ***(Wiley Online Library) (IF-1.54)***

43. **Mahesh R,** Jindal A, Gautam B, Bhatt S, Pandey D. Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative – An investigation using behavioral tests battery of depression. Biochemical and Biophysical Research Communications 2011; 409, 723-726. ***(Elsevier) (IF-2.40)***

44. **Mahesh R**, Devadoss T, Pandey DK, Bhatt S. Discovery of newer anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides. Bioorganic & Medicinal Chemistry Letters 2011; 21, 1253-1256. ***(Elsevier) (IF-2.90)***

45. **Mahesh R**, Devadoss T, Pandey DK, Yadav SK. Quinoxaline-2-Carboxamides: Synthesis and Pharmacological Evaluation as Serotonin Type-3 (5-HT3) receptor Antagonists. Journal of Enzyme Inhibition and Medicinal Chemistry 2011; 26, 610-615. ***(Informa Health Care) (IF-1.49)***

46. **Mahesh R**, Dhar AK, Tarasasank, TVNV, Thirunavukkarasu S, Devadoss T. Citric acid: An efficient and green catalyst for rapid pot synthesis of quinoxaline derivatives at room temperature. Chinese Chemical Letters 2011; 22, 389-392. ***(Elsevier) (IF-1.21)***

47. Pandey DK, **Mahesh R**, Kumar AA, Rao VS, Muralidharan A, Rajkumar R. A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacology Biochemistry and Behavior 2010; 94, 363-373. ***(Elsevier) (IF-2.75)***

48. Devadoss T, Pandey DK, **Mahesh R,** Yadav SK. Effect of acute and chronic treatment with QCF-3 (4-benzyl pipirazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression. Pharmacological Reports 2010; 62, 245-257. ***(Elsevier) (IF-1.96)***

49. **Mahesh R**, Devadoss T, Pandey DK, Bhatt S, Yadav SK. Design, Synthesis and Structure Activity Relationship of Novel Quinoxalin-2-carboxamides as 5-HT3 Receptor Antagonists for the Management of Depression. Bioorganic & Medicinal Chemistry Letters 2010; 20, 6773-6776. ***(Elsevier) (IF-2.90)***

50. **Mahesh R**, Pandey DK, Gautam B. Traumatic Brain Injury: Severity, Pathophysiology and Neurobehavioural Outcome. Pharmacologyonline Letters 2010; 1, 546-555. ***(IF-0.16)***

51. **Mahesh R**, Pandey DK, Bhatt S, Gautam B. Depression Associated Disorders: Comorbidity, Neurobiological and Neurobehavioural Link. Pharmacologyonline Letters 2010; 1, 386-405. ***(IF-0.16)***

52. **Mahesh R,** Pati D, Pandey DK, Kurdekar V, Jadhav HR. Anti-depressant-like activity of Mucuna Pruriens, a traditional Indian herb in animal models of depression. Pharmacologyonline Archives 2010; 1, 537-551. ***(IF-0.16)***

53. Rajkumar R, **Mahesh R.** The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target? Journal of Psychopharmacology 2010; 24, 455-469. ***(Sage Journals) (IF-3.37)***

54. Rajkumar R, Pandey DK, **Mahesh R**, Radha R. 1-(m-Chlorophenyl) piperazine Induces Depressogenic-like Behaviour in Rodents by inhibiting the neuronal 5-HT2A receptors: Proposal of a Modified Rodent Anti-depressant assay.European Journal of Pharmacology 2009; 608, 32-41. ***(Elsevier) (IF-2.592)***

55. Pandey DK, Yadav SK, **Mahesh R,** Ramamoorthy R. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: A model of comorbid depression and anxiety. Behavioural Brain Research 2009; 205, 436-442. ***(Elsevier) (IF-3.32)***

56. Pandey DK, **Mahesh R.** Depression: Current Therapy and novel Anti-depressant Drug Targets. Pharmacologyonline Letters 2009; 3, 993-1012. ***(IF-0.16)***

57. Bhatt S, **Mahesh R**, Pandey DK, Pai KSR TAFI: A Potential Target for Fibrinolytic Drugs. Pharmacologyonline Letters 2009; 3, 770-781. ***(IF-0.16)***

58. Ramamoorthy R, **Mahesh R**, Borah M. Anti-depressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behavioural Pharmacology 2008; 19, 29-40. ***(Lippincott Williams and Wilkins) (IF-2.30)***

59. Pandey DK, Ramamoorthy R, **Mahesh R**, Radha R. Depressant-like effects of Parthenolide in rodent behavioural anti-depressant test battery. Journal of Pharmacy and Pharmacology 2008; 60, 1643-1650. ***(Wiley Online Library) (IF-2.03)***

60. Rajkumar R, **Mahesh R.** Assessing the Neuronal Serotonergic Target based Anti-depressant Stratagem: Impact of in vivo Interaction Studies and Knockout models. Current Neuropharmacology 2008; 6, 215-234. ***(Bentham Science)(IF-3.08)***

61. **Mahesh R,** Rajkumar R, Minasri B, Perumal V. Potenatial anti-depressants; Pharmacology of 2 (4-methyl piperazine -1yl) -1, 8 naphthyridine -3-carbonitrile in rodent behavioural models. Pharamzie 2007; 63, 23-30. ***(Govi-Verlag) (IF-0.96)***

62. **Mahesh R**, Perumal VR, Pandi, PV. Microwave–assisted solvent–free synthesis of 3-[(4-substitutedpiperazin-1-yl) alkyl] imidazo [2, 1-b][1,3] benzothiazol-2 (3H)-ones as Serotonin3 (5-HT3) receptor antagonists. Pharmazie 2005; 60, 411-414. ***(Govi-Verlag) (IF-0.96)***

63. **Mahesh R**, Perumal VR, Pandi, PV. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie 2005; 60, 83-96. ***(Govi-Verlag) (IF-0.96)***

64. **Mahesh R**, Perumal VR, Pandi PV. Microwave assisted synthesis of 2- (4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorganic Medicinal Chemistry Letter 2004; 14, 5179-5181. ***(Elsevier) (IF-2.90)***

65. **Mahesh R**, Perumal V, Pandi PV. Pharmacophore Based Synthesis of 3-Chloroquinoxaline-2-carboxamides as Serotonin3 (5-HT3) Receptor Antagonist. Biological and Pharmaceutical Bulletin 2004: 27, 1403-1405. ***(The Pharmaceutical Society of Japan) (IF-1.849)***

National

66. Kurhe Y, **Mahesh R** (2017). Ondansetron ameliorates depression associated with obesity in high fat diet fed experimental mice: an investigation based on the behavioral, biochemical and molecular approach. Indian J Pharmacol **2017;**49,290-296. ***(Medknow) (IF-0.68)***

67. Mundra S, **Mahesh R**. Insignificant *in vitro* falcipain-2 inhibitory activity of novel 2-(4-(substituted benzoyl) piperazine-1-yl)-*N*-phenylacetamide derivatives. Journal of Pharmaceutical Negative Results 2015; 6, 20-26. ***(Medknow)***

68. Prabhakar V, Gupta D, Kanade P, **Radhakrishnan M**. Diabetes-associated depression: The serotonergic system as a novel multifunctional target. Indian Journal of Pharmacology 2015; 47, 4-10. ***(Medknow) (IF-0.68)***

69. Kurhe Y, **Mahesh R**, Devadoss T, Gupta D. Antidepressant-like effect of a novel 5-HT3 receptor antagonist N-(benzo [d] thiazol-2-yl)-3-ethoxyquinoxalin -2-carboxamide 6k using rodents behavioral battery tests.Journal of Pharmacology & Pharmacotherapeutics 2014; 5, 197-202. ***(Medknow) (IF-0.68)***

70. Kurhe YV, **Mahesh R**, Thangaraj D, Gupta D. Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide(6k)using battery tests for anxiety in mice. Indian Journal of Pharmacology 2014; 46, 100-104. ***(Medknow) (IF-0.68)***

71. Bhatt S, **Mahesh R**, Jindal A, Devadoss T, Dhar AK. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice. Indian Journal of Pharmacology 2014; 46, 191-196. ***(Medknow) (IF-0.58)***

72. Jindal A, **Mahesh R**, Bhatt S. Anxiolytic-like effect of etazolate, a type 4 phosphodiesterase inhibitor in experimental models of anxiety. Indian Journal of Experimental Biology 2013; 51, 444-449. ***(NISCAIR) (IF-1.195)***

73. Bhatt S, **Mahesh R**, Jindal A, Devadoss T. Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist. Indian Journal of Experimental Biology 2013; 51, 435-443. ***(NISCAIR) (IF-1.195)***

74. Bhatt S, **Mahesh R**, Jindal A, Devadoss T. Anxiolytic-like effect of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) in experimental mouse models of anxiety. Indian Journal of Experimental Biology 2013; 51, 510-514. ***(NISCAIR) (IF-1.195)***

75. Bhatt S, **Mahesh R**, Jindal A, Devadoss T. Antidepressant- like effect of novel 5-HT3 receptor antagonist N-n-butyl-3- ethoxyquinoxalin-2-carboxamide (6p)- an approach using rodent behavioral antidepressant tests battery. Indian Journal of Pharmacology 2013; 45, 348-353. ***(Medknow) (IF-0.58)***

76. Kurhe YV, **Mahesh R**, Gupta D, Thangaraj D. Effect of a novel 5-HT3 receptor antagonist 3-methoxy-n-p-tolylquinoxalin-2-carboxamide (QCM-4) on the acute and chronic rodent models of depression. International Journal of

Pharmacy and Pharmaceutical Sciences 2013; 5, 567-573. ***(Academic Sciences)(IF-0.91)***

77. Gupta D, **Radhakrishnan M**, Bhatt S, Kurhe Y. Role of Hypothalamic-pituitary-adrenal-axis in Affective Disorders: Anti-depressant and Anxiolytic Activity of Partial 5-HT1A Agonist in Adrenalectomised Rats. Indian Journal of Psychological Medicines 2013; 35, 290-8. ***(Medknow)***

78. Bhatt S, **Mahesh R**, Devadoss D, Jindal A. Anxiolytic-Like Effect of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in Experimental Mouse Models of Anxiety. Indian Journal of Pharmacology 2013; 45, 248-251. ***(Medknow) (IF-0.58)***

79. **Mahesh R**, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Dhar AK, Pandey DK. Anti-depressant Like Effect of Novel 5-HT3 Receptor Antagonist, (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in Acute and Chronic Animal Models of Depression. Indian Journal of Pharmaceutical Education and Research, 2013; 47, 71-81**. *(APTI) (IF-0.15)***

80. Kumar B, Jindal A, Pandey DK, Bhatt S, Devadoss D, **Mahesh R**. Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models. Indian Journal of Experimental Biology 2012; 50, 625-632. ***(NISCAIR) (IF-1.195)***

81. **Mahesh R,** Kumar B, Jindal A, Bhatt, S, Devadoss T, Pandey DK. Antidepressant-like activity of (4-phenylpiperazin-1-yl) (quinoxalin-3-yl) methanone (4a), a Novel5-HT3 receptor antagonist: An investigation in behaviour-based rodent models of depression. Indian Journal of Pharmacology, 2012; 44, 560-565. ***(Medknow) (IF-0.58)***

82. Jindal A, **Mahesh R**, Gautam B, Bhatt S, Pandey D. Evaluation of anti-diabetic activity of methanolic extract from the bark of Atalantia monophylla (Linn.) in alloxan-induced diabetic mice. International Journal of Green Pharmacy 2012; 6, 133-137. ***(Medknow)***

83. **Mahesh R**, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Pandey DK. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). Journal of Young Pharmacist 2012; 4, 235-244**. *(Elsevier)***

84. Jindal A, **Mahesh R,** Singh K, Bhatt S, Gautam, B; Pandey D. Ameliorative Effect of Wortmannin and Rapamycin Treatment on Obesity Markers in High Fat Diet feed rats. Indian Journal of Pharmaceutical Education and Research 2011; 45, 333-338. ***(APTI) (IF-0.15)***

85. **Mahesh R**, Pandey DK, Bhatt S, Gautam B. Anti-depressant like Effect of Pimozide in Acute and Chronic Animal Models of Depression. Indian Journal of Pharmaceutical Education and Research 2011; 45, 46-53. ***(APTI) (IF-0.15)***

86. Gupta D, Devadoss T, Bhatt S, Gautam B, Jindal A, Pandey D, **Mahesh R.** Antidepressant like effect of a novel serotonin type-3 (5HT3) receptor antagonist in rodent models of depression. Indian Journal of Experimental Biology, 2011; 49, 619-626. ***(NISCAIR) (IF-1.195)***

87. Chaudhary S, **Mahesh R,** Gautam B, Jindal A, Bhatt S. Serotonin 5-HT6 Receptor: A Potential Target For Cognition. International Research Journal of Pharmacy 2010; 1, 7-18. ***(Moksha Publishing House)***

88. **Mahesh R**, Aprna A, Ramakrishnan V, George J, Pandey DK. Demographic Study On Disease Prevalence And Their Treatment Pattern In A Local Hospital Of A Semi-Urban Community. International Journal of Research in Ayurveda and Pharmacy 2010; 1, 569-564. ***(Moksha Publishing House)***

89. **Mahesh R**, Devadoss T, Pandey DK, Baldev G, Jindal A, Shvetank B. Depression Associated Comorbid Cardiovascular And Metabolic Complications International. Journal of Research in Ayurveda and Pharmacy 2010; 1, 23-32. ***(Moksha Publishing House)-Invited article***

90. **Mahesh R**, Sharma P, Gautam BK, Bhatt S, Pandey DK. Antidepressant-like activity of cannabinoid type-1 receptor antagonist, rimonabant: behavioural investigation in animal model of depression. International Journal of Pharma and Biosciences 2010; 1, 1-13. ***(Indian Science)-Invited article***

91. **Mahesh R**, Pandey DK, Katiyar S, Kukade G, Viyogi S, Rudra A. Effect of Anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats. Indian Journal of Experimental Biology 2010; 48, 466-473. ***(NISCAIR) (IF-1.195)***

92. Pandey DK, Pati D, Joshi A, **Mahesh R.** Chronic Unpredictable Stress: Possible Animal Model of Comorbid Depression. International Journal of Preclinical and Pharmacy Research 2010; 1, 54-65. ***(Indian Science)-Invited article***

93. **Mahesh R**, Shruti V, Pandey DK, Yadav SK. Evaluation of Anti-depressant and Analgesic- Like Activity of Ondansetron in Rodents model of Comorbid Pain and Depression. Indian Journal of Pharmaceutical Education and Research 2010; 44, 160-170. ***(APTI) (IF-0.15)***

94. Gautam BK, Rana M, Pandey DK, **Mahesh R**, Singh M. The Possible Role of PI3K/Akt Pathway in Partial Abdominal Aortic Constriction (PAAC) Induced Pathological Cardiac Hypertrophy. International Journal of Pharma Recent Research 2009; 1, 1-11.

95. Rajkumar R, **Mahesh R.** Behavioural Investigation of Ondansetron in Rodent Models: Are 5-HT3 Receptors Potential Neuronal Targets of Depression? AAPS J 2007; 9(S2), *Abstract no M1160*

96. **Mahesh R**, Perumal VR. Microwave-induced Mannich reaction– Synthesis of some Mannich derivatives of p-aminophenol. Indian Journal of Chemistry 2004; 43, 1012-1014. ***(NISCAIR)***

Conference Presentations *(International and National)*

International

1. Kurhe Y, **Mahesh R**, Thangaraj D. Mechanisms linking depression associated with obesity through serotonergic modulation in experimental mice. Society for Neuroscience (SfN) 46th Annual Meeting, Neuroscience 2016, Nov 12-16, 2016, San Diego, California, United States.

2. Gupta D, **Mahesh R**. 6z, a novel 5HT3 receptor antagonist reverses depression-like behavior in streptozotocin-induced diabetic mice by normalizing serotonin deficiency and HPA-axis hyperactivity. 14th Meeting of the Asian Pacific Society for Neurochemistry, Aug 27-30, 2016, Kuala Lumpur, Malaysia.

3. Kurhe Y, **Mahesh R**, Thangaraj D. Serotonergic type 3 receptor antagonist (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone (4a) attenuates depression co-morbid with obesity by promoting serotonergic neuromodulation and reversing insulin resistance in experimental mice. IBRO/APRC Varanasi School (Molecular Advancements in Neurobiology), Sept 5-20, 2015, Varanasi, India.

4. Gupta D, **Mahesh R**. 4i (N-(3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5HT3 antagonist, reverses diabetes-induced depressive phenotype. 25th ISN-APSN Joint Biennial Meeting organized by Australasian Society for Neuroscience (ANS), August 23-27, 2015, Cairns, Australia.

5. Gupta D, **Mahesh R**, Kurhe Y, Thangaraj D. Antidepressant-like effects of EQC-34,a novel 5HT-3 receptor antagonist in neurobehavioral mouse model of depression. International Conference on Pharmacy and Pharmacology (ICPP)-2014, 26-27 September, 2014, London, UK.

6. Kurhe Y, **Mahesh R**, Gupta D, Thangaraj D. Antidepressive-Like Effect Of A Novel 5-HT3 Receptor Antagonist (4a) Against Depression Co-Morbid With Obesity In Mice Subjected To Chronic Stress. FENS Forum of Neuroscience, 5-9 July, 2014, Milan, Italy.

7. **Mahesh R**, Mundra S, Mohammed A. Design and synthesis of falcipain-2 Inhibitor's as a potential Antimalarial Agents. Chemical Biophysics Symposium, 21-23 April, 2013, Toronto, Canada.

8. **Mahesh R**, Mundra S. Design, Synthesis of Novel Antimalarial agents. Biological Therapeutics Symposium, 2-3 May 2013, University of Toronto, Toronto-Canada.

9. **Mahesh R**, Mundra S. Fluorimetric assay for falcipain-2 activity using Victor multi-label counter. Biomedical Engineering & Science Technology (BEST) Symposium at St. Michael's Hospital, 13 June, 2013, Toronto-Canada.

National

10 Sushil Kumar Yadav, R Mahesh, Vishal Saxena Milk derived peptide induced histopathological changes in rat bone. International Conference on Life Science Research & its Interface with Engineering and Allied Sciences (LSRIEAS 2018) organized at BITS, Pilani, Pilani Campus, Nov 1-3, 2018. (Best Poster Award)

11 Dahitule Gauri Chandrakant, Radhakrishnan Mahesh, Telescopic Forecasting And Preventive Strategies For Alzheimer's Disease, International Conference on Frontiers in Neuroscience and Neurochemistry: Dynamic Challenges and Approaches, Society for Neurochemistry India (SNCI), Jamia Hamdard, Delhi, 10-12 Oct., 2019

12 Sushil Kumar Yadav, R Mahesh, Vishal Saxena Separation and Analysis of Beta Casein Variants from Cow Milk and their Application in Solubility Enhancement of Poorly Water Soluble Drug. "8th Annual International Conference on Dissolution Science and Applications" - Disso India 2019 organized at NIPER-SAS Nagar, September 11 - 13, 2019.

13 Sushil Kumar Yadav, R Mahesh, Vishal Saxena Development of new analytical method for the analysis of β- casein variants in cattle from Pilani region. International Conference on Challenges in Drug Discovery and Delivery (ICCD3-2017), organized at BITS, Pilani, Pilani Campus, March2-4, 2017

14 Sushil Kumar Yadav, R Mahesh, Vishal Saxena Epidemiological study of beta-casein alleles. Golden Jubilee Concluding Celebrations & Annual Confrence of Indian Pharmacological Society (IPSCON-2017), organized by Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS, Mumbai, India, Feb 15-17, 2018

15 Kurhe Y, Mahesh R. Ondansetron ameliorates depression associated with obesity in high fat diet fed experimental mice: an investigation based on the behavioral, biochemical and molecular approach. 49th Annual Conference of Indian Pharmacological Society (IPSCON-2016) on October 20-23, 2016, PGIMER Chandigarh, Punjab, India.

16 Mundra S, Mahesh R. Design, Synthesis and Structure Activity Relationships of Novel Peptidomimetics as Potential Anti-malarial Agents. 49th Annual Conference of Indian Pharmacological Society (IPSCON-2016) on October 20-23, 2016, PGIMER Chandigarh, Punjab, India.

17 Mundra S, Mahesh R. Identification of novel class of falcipain-2 inhibitors as potential anti-malarial agents. Organic Chemistry in Sustainable Development: Recent advantages and future challenges (OCSD-2016), August 29-30, 2016, BITS Pilani, Pilani Campus, Pilani, Rajasthan, India.

18 Kurhe Y, Mahesh R. High fat diet fed obese rats injected with exogenous corticosterone: an animal model to study depressive-phenotypes associated with obesity. DBT, ICMR and APTI Sponsored Two Days National Conference on "Contemporary Technologies in Drug Delivery and Envisaged Future Trends" on August 12-13, 2016 at Geetanjali Institute of Pharmacy, Geetanjali University, Udaipur, Rajasthan, India.

19 Bhatt S, Mahesh R, Devadoss T, Jindal A. Pharmacological profiling of quinoxalin derivative (6g), a novel serotonergic 5-HT3 receptor antagonist for its antidepressant-and anxiolytic-like activity in traumatic brain injury model in rats. IPC Conference, December 19-21, 2015, JSS University, Mysore, India.

20 Mundra S, Mahesh R. Evaluation of novel class of falcipain-2 inhibitors as potential anti-malaria agents. New Frontiers In Chemistry-From Fundamentals To Applications (NFCFA 2015), December 18-19, 2015, BITS Pilani, Goa Campus, Goa, India.

21 Mundra S, Mahesh R. Design, Synthesis and careening of falcapin-2 inhibitors as novel anti-malarial agents. 2nd NirmaInstitute ofPharmacyInternationalConference, NIPICON January 23-25, 2014, Ahmedabad, India.

22 Mahesh R, Jindal A, Bhatt S. Etazolate rescues behavioral deficits in chronic unpredictable stress models of depression by the modulation of HPA axis, BDNF signaling andantioxidant defence system: possible mechanism(s) of neuroprotection. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

23 Mahesh R, Bhatt S, Devadoss T, Jindal A. Neuropharmacological effect of (4-benzylpiperazin-1-yl) (3-methoxyquinoxalin-2-yl) methanone (qcm-15), a potential 5-ht3 receptor antagonist on chronic unpredictable mild stress-induced changes in behavior and brain oxidative stress in mice. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

24 Mahesh R, Dhar AK, Jindal A Bhatt S. 2-(4-substitutedpiperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: novel 5-HT3 receptor antagonists as potential anxiolytics. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

25 Muthu VS, Mahesh R, Jindal A. Design, synthesis and pharmacological evaluation of novel Phosphodiesterases-4 inhibitors as potential anti-depressants. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

26 Gupta D, Mahesh R, Kurhe Y. Diabetes associated depression: ondansetron, as an antidepressant for streptozotocin induced diabetes associated depression in mice. Journal of Diabetes and Metabolism, OMICS Group Conferences, 3: 8, 133, 24-26th September 2012, Hyderabad.

27 Gupta D, Mahesh R, Bhatt S, Devadoss T. Antidepressant like activity of buspirone and role of HPA axis dysregulation in depression. National conference on pharmacy and pharmaceutical sciences-from bench to market. Pharmanext (AIPER), 28-29th April 2012, Madhya Pradesh.

28 Mahesh R, Bhatt S, Panjawani R, Devadoss T, Jindal A. Neuro-pharmacological evaluation of novel serotonin type-3 (5-HT3) receptor antagonists qcm-15, qcm-16, qct-16 & qct-22 (quinoxaline derivatives) for their anxiolytic potential. Indian Pharmaceutical Association Convention, 17-18th March 2012, Manipal.

29 Mahesh R, Mundra S, Devadoss T, Dhar AK, Sudali MV. Design and synthesis of pyrimidine scaffold for their kinase inhibitor activity. National conference of Pharmanext 19-20 February 2012, Aligarh.

30 Mahesh R, Dhar AK, Jindal A, Muthu VS, Mundra S. Design, synthesis and pharmacological evaluation of Novel 2-(4-substituted piperazine 1-yl)-1,8-naphthyridine 3-carboxylic acids as 5-HT3 receptor antagonists for the management of depression. Indian Pharmaceutical Association Convention, 17-18th March 2012, Manipal.

31 Mahesh R, Mundra S, Dhar AK, Sudali MV. Design and synthesis and screening of falcipain-2 Inhibitors. National conference ''Molecular Diagnostics: Challenges vis-à-vis Growth Potential"- Organized by Department of Biotechnology and Confederation of Indian Industries. 8 June 2012, Delhi.

32 Mahesh R, Sudali MV, Murugesan S, Dhar AK, Mundra S, Jindal A. "Design and docking study of 4-benzyl-3-oxo-3,4-dihydroquinoxaline-2-carboxamide analogues as phosphodiestrase-iv (PDE-IV) inhibitors". Indian Pharmaceutical Association (IPA) Convention 17-18 March, 2012, Manipal.

33 Mahesh R, Kumar B, Jindal A, Pandey D, Bhatt S, Devadoss T. Antidepressant like activity of (4-phenylpiperazin-1-yl) (quinoxalin-3-yl) methanone (4a), a novel 5 HT3 receptor antagonist: An investigation in behaviour-based rodent models. Indian Pharmacological Society Conference, 19-21th December 2011, Manipal (Oral Presentation).

34 Mahesh R, Jindal A, Kumar B, Bhatt S, Pandey D. Rolipram, a phosphodiesterase 4 (PDE4) enzyme inhibitor as a potential anti-depressant: An investigation using behavioral tests battery of depression. Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

35 Mahesh R, Dhar A, Singh S, Jindal A, Sharma A, Bhatt S. Evaluation of antianxiety like activity of 2-(-4-phenylpiperazine-1-yl) 1.8-Naphthridine-3-carboxylic acid(7a) A serotonin type-3(5-HT3) receptor antagonist: An investigation using behavioural test battery of anxiety. Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

36 Mahesh R, Dhar A, Sharma A, Jindal A, Singh S, Kumar B. Behavioral investigation on antidepressant like activity of 2-(-4-phenylpiperazine-1-yL) 1,8-Naphthlidine-3-carboxylic acid(7a)Anovel serotonin type-3(5-HT3)receptorantagonist:for comorbid depression with cancer chemotherapy induced nausea and vomiting(CINV). Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

37 Mahesh R, Srinivasrao B, Devadoss T, Jindal A, Bhatt S, Kumar B. Studies on the analgesic and anti-inflammatory activity of n-[2-(1h-indol-3-yl)ethyl]quinoxalin-2-caboxalicacid (qcf-20), a novel serotonin type-3 (5-ht3) receptor antagonist. Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

38 Bhatt S, Panjwani R, Devadoss T, Gautam BK, Jindal A, Mahesh R. To evaluate a novel 5 HT3 receptor antagonist 3-Ethoxy-N-Propylquinoxaline-2-carboxamide (EPQC) for its anti-depressant and anxiolytic potential. APTICON 7-9th October 2011, Moga, Punjab.

39 Gupta D, Mahesh R, Bhatt S, Devadoss T. Pharmacological evaluation of novel serotonin type-3 (5HT3) receptor antagonist for comorbid depression and anxiety in rodent models of comorbid disorder. Indian Pharmaceutical Association Convention, 19-20th February 2011, Indore.

40 Mahesh R, Pandey D, Pinky Sharma. 1(m- chlorophenyl) Pipirazine (mCPP) induces depressogenic- like behaviour in rodent by stimulating the neuronal 5-HT receptor as a potential rodents Anti-depressant assays. Pharmanext Conference, 18-19th September 2010, Jaipur.

41 Mahesh R, Bhatt S , Gautam B, Pandey D, Devadoss T. Evaluation of novel 5-HT3 antagonist as a potential anti-depressant in comorbid condition. Pharmanext Conference, 18-19th September 2010, Jaipur.

42 Mahesh R, Gautam B, Pandey D, Bhatt S, Ramamoorthy R. Hyposerotonergic consequences of parthenolide in a battery of rodents behavioural Assays of depression. Pharmanext Conference, 18-19th September 2010, Jaipur.

43 Mahesh R, Jindal A, Kurdekar A, Jhadav H, Bhatt S, Gautam BK, Pandey DK. Evaluation of Anti-oxidant, Analgesic and Anti-inflammatory activity of Methanolic Bark extract of Atalantia monophylla. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

44 Mahesh R, Gumpally C, Bhatt S, Thangaraj Devadoss, Dilip Pandey, Gautam B, Ankur Jindal. Evaluation of novel sertonergic type-3 receptor antagonist quinoxalin-2-carboxylic acid derivative (qct-22) for their antidepressant potential. Indian Pharmacological Society Conference 14-16th December 2010, Hyderabad.

45 Mahesh R, Chaudhary S, Bhatt S, Devadoss T, Pandey D, Gautam B, Jindal A. Preclinical evaluation of quinoxalin-2-carboxylic acid derivative (qct-16), a novel sertonergic modulator for their anti-depressant potential. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

46 Mahesh R, Modak N, Bhatt S, Devadoss T, Pandey D, Gautam B, Jindal A. Novel Quinoxaline Derivative: A Potential Anti Depressant For Treatment Resistant Depression. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

47 Mahesh R, Bhatt S, Devadoss T, Gautam B, Soni P, Gumpally C, Jindal A, Pandey D. Pharmacological profiling of quinoxalin-2-carboxylic acid derivative (qcm-16), a novel sertonergic modulator for its anti-depressant potential. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

48 Mahesh R, Bhatt S, Devadoss T, Gautam B, Jindal A, Pandey D. Qcm-13(n-cyclohexyl-3-methoxyquinoxalin-2carboxamide) a novel antidepressant; pharmacological evaluation of the potential serotonin type 3 (5-ht3) receptor antagonist. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad. a novel antidepressant; pharmacological evaluation of the potential serotonin type 3 (5-ht3) receptor antagonist. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

49 Mahesh R, Pandey D, Sharma P. 1(m- chlorophenyl) Pipirazine (mCPP) induces depressogenic- like behaviour in rodent by stimulating the neuronal 5-HT receptor as apotential rodents Anti-depressant assays. Pharmanext Conference, 18-19th September 2010, Jaipur.

50 Mahesh R, Pandey D, Devadoss T. Effect of acute and chronic treatment with QCF-3 (4-benzyl pipirazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression. Indian Pharmacological Society Conference, 10-12th December 2009, Kolkata.

51 Mahesh R, Baldev G, Shvetank, Bhatt, Pandey D. Pimozide 5-HT7 / D2 antagonist evaluation in acute and Chronic model of depression. Indian Pharmacological Society Conference, 10-12th December 2009, Kolkata.

52 Mahesh R, Devadoss T,Pandey DK, Yadav S. Synthesis, 5-HT3 antagonist and anti-depressant evaluation of novel quinoxaline derivatives. National Conference on Emerging Trends In Life Sciences Research, 6-7th March 2009, BITS Pilani, Rajasthan, India.

53 Pandey DK, Mahesh R. Antidepressant-like effect of serotonin 2a (5-HT2a) receptor antagonist in rodents: approaching to novel quick-onset antidepressants. National Conference on Emerging Trends In Life Sciences Research, 6-7th March, 2009, BITS Pilani, Rajasthan, India.

54 Mahesh R, Bhatt S, Devadoss T, Joshi A, Pandey DK, Yadav S. Evaluation of novel serotonin type 3 (5-HT3) receptor antagonist for their anti-depressant like Activity. APTICON, 3-4th October 2009, Jodhpur, Rajasthan.

55 Mahesh R, Sharma P, Pandey DK, Yadav S. Rimonabant : A potential drug for comorbidobesityand depression. APTICON3-4th October 2009,Jodhpur,Rajasthan.

56 Mahesh R, Pati D, Pandey DK, Kurdekar V, Jadhav HR. Mucuna Pruriens: A traditional Indian anti-parkinsonian herb with potent anti-depressant activity. APTICON 3-4th October 2009, Jodhpur, Rajasthan.

57 Mahesh R, George J, Vidya R, Pandey DK, Jain RK. Alok T. Demographic study on disease prevalence and their treatment pattern in a local hospital of semi urban community. APTICON, 3-4th October 2009, Jodhpur, Rajasthan.

58 Mahesh R, Devadoss T, Pandey DK, Yadav S. 3-ethoxyquinoxalin-2-carboxamode: A new series of potential 5-HT3 receptor antagonist for the management of depression. APTICON, 3-4th October 2009, Jodhpur, Rajasthan.

59 Pandey DK, Mahesh R, Yadav SK. Neuro-Psychiatric Sequelae of Depression and Anxiety Following Impact Accelerated Traumatic brain Injury in Rats: A Model for Comorbidity. International Symposium on Pharmaceutical and Biomedical Analysis, 1-4th March 2009, Agra India.

60 Aparna M, Mahesh R, Pandey DK, Agarwal R, Sarkar S. Neuroprosthetics as Non-Pharmacological Intervention Techniques. International Symposium on Pharmaceutical and Biomedical Analysis, 1-4th March 2009, Agra India. Intervention Techniques. International Symposium on Pharmaceutical and Biomedical Analysis, 1-4th March 2009, Agra India.

61 Pandey DK, Mahesh R, Rajkumar R, Shruti K. Effects of Anti-depressants on Behavioural consequences following impact accelerated traumatic brain injury in rats: analysis by rodent behavioural test battery. Indian Pharmacological Society Conference, 18-20th December 2008, AIIMS Delhi.

62 Sunita S, Raina A, Mahesh R, Pandey DK. Newer Mechanistic Pathways pertaining to anti-depressant action of escitalopram using acute and chronic animal model of depression and underlying immunological basis of depression. Indian Pharmacological Society Conference, 18-20th December 2008, AIIMS Delhi.

63 Shruti V, Mahesh R, Pandey DK. Anti-depressant and Analgesic Like Activity of 5-HT3 Antagonist - Novel Approach in Treating Co-morbid Depression and Pain. Indian Pharmacological Society Conference, 18-20th December 2008, AIIMS Delhi.

64 Mahesh R, Rajkumar R. Anti-depressant potential of Serotonin Type-3 Antagonists. National Symposium on Challenges in Drug Discovery research: Networking opportunities between Academia and Industries, 7-8 April, 2006 Pilani.

65 Mahesh R, Rajkumar R. Behavioural profiles of ondansetron and meta-chlorophenyl piperazine in mice models of depression. 3rd Singapore International Neuroscience Conference, National Neuroscience Institute, 23 -24th May 2006, Singapore.

66 Mahesh R, Rajkumar R, Perumal VR. Evaluation of Anti-depressant potential of 2-(4-methyl piperzin-1-yl)-1,8-naphthyridine-3- carbonitrile in mice models of depression. Indian Pharmaceutical Congress, 1-3th December 2006, Mumbai.

67 Mahesh R, Rajkumar R, Jain RK, Pareek RP. Prevalence of Gastrointestinal and Respiratory tract disorders during the months of maximum seasonal variation in a population of a semi-urban settlement. Association of Pharmaceutical Teachers of India (APTI) National Convention, 17-18th October 2005, Nagpur.

68 Mahesh R, Rajkumar R, Jain RK, Pareek RP. Analysis of disease prevalence in relation to seasonal variation in a population of a semi-urban settlement – A demographic Study, Indian Pharmaceutical Congress, 2- 4th December 2005, Hyderabad. Indian Pharmaceutical Congress, 2- 4th December 2005, Hyderabad.

69 Mahesh R, Rajkumar R. Recent advances in Central Nervous System. Indian Pharmaceutical Congress, 2- 4th December, 2005 Hyderabad.